Related Experiment Videos
Tartrazine in atopic eczema
Insights
This study investigated tartrazine (a food dye) intolerance in children with atopic eczema. Results suggest tartrazine did not significantly worsen eczema symptoms in most participants, questioning common intolerance beliefs.
Area of Science:
- Pediatric Dermatology
- Clinical Immunology
- Food Allergy and Intolerance
Background:
- Atopic eczema is a common chronic inflammatory skin condition in children.
- Parental reports often link food additives, such as tartrazine, to eczema exacerbations.
- Objective confirmation of tartrazine intolerance in pediatric atopic eczema is often lacking.
Purpose of the Study:
- To evaluate the association between tartrazine ingestion and atopic eczema severity in children.
- To objectively assess tartrazine intolerance using double-blind, placebo-controlled challenges.
Main Methods:
- Twelve children (aged 1-6 years) with severe atopic eczema and parental suspicion of tartrazine intolerance were enrolled.
- Participants underwent multiple, randomized, double-blind, placebo-controlled challenges with tartrazine (50 mg) and glucose placebo.
- Eczema severity was assessed using symptom scores and physician observer scores during challenge periods.
Main Results:
- Only one out of 12 children showed a correlation between tartrazine challenges and increased eczema symptom scores.
- Statistical analysis indicated a low probability (0.46) of this result occurring by chance.
- The study failed to confirm tartrazine intolerance in 11 of the 12 participating children.
Conclusions:
- The findings do not support a significant link between tartrazine ingestion and atopic eczema exacerbation in this pediatric cohort.
- Tartrazine intolerance was not confirmed in the majority of children evaluated, despite parental concerns.
- Further research may be needed to explore other potential triggers for eczema flares in sensitive children.
Abstract:
Multiple double blind placebo controlled challenges with tartrazine 50 mg (three challenges) and glucose placebo (three challenges) were performed in 12 children with atopic eczema aged 1 to 6 years. The children were selected on the basis of severity (regular clinic attenders) and a parental history that tartrazine provoked worsening of the eczema. In only one patient did the three tartrazine challenge periods correspond with the highest symptom scores or the highest physician observer scores, and the probability of this occurring by chance in one or more patients out of 12 was 0.46. In this sample we were unable to confirm intolerance to tartrazine in 11 out of 12 patients.